A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy
Active, not recruiting · Phase 3 · NCT03675308
Conditions: Psoriatic Arthritis
At a glance
- Research payments reported, 2025
- $626,987
- U.S. investigators named
- 20
- Sites paid
- 21
- Planned or actual enrollment
- 964
About the trial
- Sponsor
- AbbVie
- Tested
- Placebo (biological), Risankizumab (biological)
- Dates
- Started 2019-03-25; completion 2026-09-28
- Results posted
- Yes
The purpose of this study is to compare the safety and efficacy of risankizumab versus placebo in participants with moderately to severely active psoriatic arthritis (PsA).
From ClinicalTrials.gov, last updated 2025-08-05. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $626,987 in research payments for this study in 2025 (148 payments).
Products named: Skyrizi
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Leslie Mccasland, M.D. Rheumatology · Jonesboro, AR
- Joy Schechtman, DO Rheumatology · Peoria, AZ
- Charles G. Peterfy, M.D., PH.D. Radiology · Kentfield, CA
- Tien I K. Su, M.D. Rheumatology · Whittier, CA
- Joseph Z. Forstot, MD Rheumatology · Boca Raton, FL
- Swati M. Shah, MBBS Rheumatology · Jacksonville, FL
- Guillermo J. Valenzuela, MD Specialist · Plantation, FL
- Debra J. O'malley, MD Critical Care Medicine · Melrose Park, IL
- Saad Tariq, MD Rheumatology · Rockford, IL
- William E. Palmer, MD Radiology · Boston, MA
- Joshua P. June, DO Rheumatology · Lansing, MI
- Monika Mohan, M.D. Rheumatology · Okemos, MI
- Roger J. Diegel, MD Rheumatology · Kalispell, MT
- Melvin A. Churchill JR., M.D. Rheumatology · Lincoln, NE
- Isam Diab, MD Rheumatology · Middleburg Hts, OH
- Oscar Soto Raices, MD Rheumatology · San Juan, PR
- Shaikh Ali, MD PA Rheumatology · Tomball, TX
- Dhiman Basu, MD Rheumatology · Colleyville, TX
- Tamar F. Brionez, MD Rheumatology · The Woodlands, TX
- Wassim S. Saikali, MD Rheumatology · Beckley, WV
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Spire Sciences Inc $279,960
- Arthritis and Rheumatism $45,643
- Physician Research $38,192
- Rheumatology and Pulmonary Clinic $33,158
- Dr Tamar F Brionez MD PA $26,639
- Mgpo Radiology Associates $25,420
- Logan Health Medical Center, MT $23,695
- Biovin Enterprises LLC $21,951
- Jacksonville Ctr for Clinical Rsrch $21,630
- Mindful Medical Research $20,243
- Precision Comprehensive Clinical $18,871
- June Do PC $11,883
- Dynamed Clinical Research LP $7,815
- Orthomidwest PLLC $7,542
- Hmd Research LLC $6,978
- Affinity Health Corp $6,922
- Iris Research and Development LLC $6,903
- Rasf-Clinical Research Center $6,807
- Paramount Medical Research $6,580
- Advanced Rheumatology PC $5,890
- Sunvalley Arthritis Center $4,267
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.